https://www.selleckchem.com/pr....oducts/ex229-compoun
0 months. These findings suggest that the use of highly conformal Cs-131 brachytherapy is a promising treatment for patients with recurrent GBM with minimal risk of development of RN. The purpose of this study was to evaluate whether the dose to bladder neck (BN) is a predictor of acute and late urinary toxicity after high-dose-rate brachytherapy (HDR boost for prostate cancer. Between 2014 and 2016, patients with prostate cancer treated at our institution with external beam radiation therapy and 15Gy single-fraction HDRB b
Curtir
Comentario
Compartilhar
